Heartflow develops AI-driven software for diagnosing and managing coronary artery disease. The company's core technology uses machine learning to generate detailed 3D models of the heart and simulate blood flow from standard coronary CT angiography images, helping clinicians assess blockages and their functional significance without invasive procedures.
HeartFlow One, the company's platform, integrates three analytical tools: Roadmap Analysis for visualizing coronary narrowings, FFRCT Analysis for assessing blood-flow impact through personalized simulations, and Plaque Analysis for characterizing atherosclerosis. The technology aligns with ACC/AHA cardiology guidelines and provides decision support throughout the diagnostic pathway.
The company operates at substantial clinical scale. Its software has been used in the care of over 600,000 patients across more than 1,800 institutions globally. Insurance coverage extends to 99.5% of U.S. lives through Medicare and major commercial carriers. Heartflow is publicly traded on Nasdaq under ticker HTFL and maintains offices in the United States, Europe, and Japan, with headquarters in San Francisco.
The platform is supported by more than 625 peer-reviewed publications in medical literature, establishing its clinical validation in cardiology research and practice.
